Processa Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Processa Pharmaceuticals's estimated annual revenue is currently $3.1M per year.
- Processa Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Processa Pharmaceuticals has 20 Employees.
- Processa Pharmaceuticals grew their employee count by 11% last year.
Processa Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO and Board Director | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Development Officer (CDO) | Reveal Email/Phone |
4 | Chief Business - Strategy Officer | Reveal Email/Phone |
5 | Chief Business - Strategy Officer | Reveal Email/Phone |
6 | CFO | Reveal Email/Phone |
7 | Chief Administrative Officer | Reveal Email/Phone |
8 | COO | Reveal Email/Phone |
9 | VP Clinical Operations | Reveal Email/Phone |
10 | VP Project Management | Reveal Email/Phone |
Processa Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Processa Pharmaceuticals?
Processa Pharmaceuticals was founded in October 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The company is headquartered in Hanover, Maryland.
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.6M | 20 | 11% | N/A |
#2 | $2.2M | 21 | 62% | N/A |
#3 | $2.1M | 21 | -12% | N/A |
#4 | $2.1M | 21 | N/A | N/A |
#5 | $4.3M | 21 | 5% | N/A |